SLC5A2 and kidney disorder: Antidiabetic drugs are known to inhibit the activity of glucose transporters, especially SGLT2, and this may be an effective therapy against renal diseases, such as diabetic nephropathy, chronic kidney disease, and end-stage renal disease.